Dispatch Bio debuted with $216 million in funding to develop a universal immunotherapy for solid tumors. The approach uses a dual mechanism with a viral vector tagging cancer cells and CAR-T or other powerful immunotherapies for targeted clearance. Co-founded by CAR-T pioneer Carl June and other leading scientists, Dispatch aims to overcome solid tumor barriers that have limited cell therapy effectiveness. The company expects to begin clinical testing next year.